Fig. 6: IMSA101-induced IL-18 secretion enhances CART function and anti-tumor response in vivo. | Nature Communications

Fig. 6: IMSA101-induced IL-18 secretion enhances CART function and anti-tumor response in vivo.

From: The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion

Fig. 6

a Schematic of experimental design for testing IL-18 receptor negative CART in a syngeneic mouse model. Icons of this figure created with BioRender.com. b, c In vitro assays confirm that murine CART, either wild type (WT-CART) or IL-18 receptor negative (IL18R-neg. CART) (b) secrete IL-2, TNF, and IFNg and (c) show antigen-specific cytolytic activity after co-incubation with B16-huCD19 tumor cells. Mean values ± SD of three biologically independent samples are shown. The values of the cytotoxicity assay were normalized to the time point of CART addition (approximately 24 h after seeding tumor cells). E:T ratio=effector cell to target cell ratio. Two-sided Mann-Whitney U test and ordinary two-way ANOVA was used for statistical analysis of cytokine and cytotoxicity assays, respectively. ns (nonsignificant) P > 0.05. d Kaplan-Meier survival curve (n = 12/cohort). Statistical significance was calculated using the log-rank Mantel-Cox test. *P ≤ 0.05; ***P ≤ 0.001. e Changes in tumor volume over time. CR complete remission. Source data and exact p-values are provided as a Source Data file.

Back to article page